Quantcast

Latest Panitumumab Stories

2011-07-27 07:35:00

QUEBEC CITY, July 27, 2011 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced the completion of patient recruitment for the ongoing Phase 3 trial with perifosine in refractory advanced colorectal cancer.

2011-07-27 07:30:00

NEW YORK, July 27, 2011 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced completion of patient enrollment in its Phase 3 registration trial of KRX-0401 (perifosine) for the treatment of refractory, advanced colorectal cancer.

2011-06-24 09:59:00

THOUSAND OAKS, Calif., June 24, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Vectibix® (panitumumab) be approved for use in the European Union (EU) in first-line in combination with FOLFOX and in second-line in combination with FOLFIRI in patients who have received first-line fluoropyrimidine-based chemotherapy (excluding...

2011-05-26 09:14:00

OMAHA, Neb., May 26, 2011 /PRNewswire/ -- Transgenomic, Inc.

2011-05-18 17:05:00

THOUSAND OAKS, Calif., May 18, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that data from studies involving nine Amgen products will be presented at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting, June 3 - 7, 2011 in Chicago.

2011-05-11 19:40:21

Some of the most effective and expensive cancer drugs, dubbed "smart drugs" for their ability to stop tumors by targeting key drivers of cancer cell growth, are not effective in some patients.

2011-04-06 15:52:35

Oncologists can use colorectal cancer patients' own immune system to boost the effects of chemotherapy and increase progression-free survival.

2011-03-30 15:05:00

THOUSAND OAKS, Calif., March 30, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) announced today that it has submitted a request to the European Medicines Agency (EMA) for a re-examination of the negative opinion issued in March by the Committee For Medicinal Products for Human Use (CHMP) for the use of Vectibix in combination with chemotherapy for patients with wild-type KRAS metastatic colorectal cancer (mCRC). Amgen believes that Vectibix in combination with chemotherapy provides an important...

2011-03-18 07:06:00

THOUSAND OAKS, Calif., March 18, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) today issued the following statement: Amgen has received notice that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion for Amgen's application to extend the marketing authorization in Europe for Vectibix(®) (panitumumab) to include combination with chemotherapy for the treatment of patients with wild-type KRAS metastatic colorectal cancer...

2011-03-01 15:00:00

REDWOOD CITY, Calif., March 1, 2011 /PRNewswire/ -- OncoMed Pharmaceuticals, Inc., a company developing novel therapeutics that target cancer stem cells, today announced the publication of preclinical data demonstrating that its lead candidate, OMP-21M18, inhibits tumor growth and reduces cancer stem cell frequency when administered alone or in combination with chemotherapy in human colorectal cancer tumors with or without KRAS mutations.


Word of the Day
whirret
  • To give a box on the ear to.
The word 'whirret' may be onomatopoeic.